secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001193125-22-148822
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cortexyme to merge with Novosteo; to issue ~6M shares, appoints Novosteo CEO as CEO
--------------------------------------------------------------------------------

- Enters definitive agreement to acquire Novosteo via reverse merger; expects to issue ~6M shares in transaction.
- Post-merger pro forma cash, cash equivalents and investments of ~$120M as of March 31, 2022.
- Dirk Thye, MD (Novosteo CEO) to become Cortexyme CEO; Chris Lowe steps down as interim CEO but remains CFO/COO.
- Philip Low, PhD appointed to Cortexyme board; independent board approves 4,000,000-share inducement plan for new hires.
- Closing expected within 30 days, subject to Novosteo stockholder approval and other customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/0001193125-22-148822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/d316217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-148822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer